Evidence map›Paper›PMID 26077911›Full record

ArticleBMC cancer2015

The role of the REG4 gene and its encoding product in ovarian epithelial carcinoma.

Shuo Chen, Wen-Feng Gou, Shuang Zhao, Zhe-Feng Niu, Yang Zhao, Yasuo Takano, Hua-Chuan Zheng

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. REG4 promotes the proliferation and anti-apoptosis of cancer.Frontiers in cell and developmental biology · 2022
    Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Regulation ofCancer genomics & proteomics
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Shuo ChenDepartment of Gynecology, The First Affiliated Hospital of China Medical University, Shenyang, 110001, China. chenshuo077003@163.com.
Wen-Feng GouDepartment of Biochemistry and Molecular Biology, College of Basic Medicine, China Medical University, Shenyang, 110001, China. xiaogouaeiou@163.com.
Shuang ZhaoDepartment of Biochemistry and Molecular Biology, College of Basic Medicine, China Medical University, Shenyang, 110001, China. zhaoshuang1235@163.com.
Zhe-Feng NiuDepartment of Biochemistry and Molecular Biology, College of Basic Medicine, China Medical University, Shenyang, 110001, China. nzf870617@126.com.
Yang ZhaoDepartment of Gynecology, The First Affiliated Hospital of China Medical University, Shenyang, 110001, China. yida.zhaoyang@163.com.
Yasuo TakanoClinical Cancer Institute, Kanagawa Cancer Center, Yokohama, 241-0815, Japan. ytakano@gancen.asahi.yokohama.jp.
Hua-Chuan ZhengDepartment of Biochemistry and Molecular Biology, College of Basic Medicine, China Medical University, Shenyang, 110001, China. zheng_huachuan@hotmail.com.
China Medical University · CNFirst Hospital of China Medical University · CNKanagawa Prefectural Hospital Organization · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough its biological function remains poorly understood, REG4 is reported to be a potent activator of the EGFR/Akt/AP-1 signaling pathway in colon cancer cells and closely linked with the inhibition of apoptosis.

methodsSKOV3 cells were transfected with a REG4-expressing plasmid or treated with recombinant REG4. We then analyzed proliferation, cell cycle, apoptosis, invasion and metastasis or expression of related molecules. REG4 expression was examined in normal ovarian tissue, benign and borderline tumors, and cancers by immunohistochemistry or real-time PCR.

resultsREG4 overexpression and the recombinant protein inhibited cell apoptosis, enhanced G2/S progression, proliferation, migration and invasion. Furthermore, expression of Wnt5a, p70s6k, survivin and VEGF expression was increased, while Bax expression was decreased at both the mRNA and protein levels compared to control or mock cells (P<0.05). REG4 mRNA levels were higher in benign tumors and primary cancer compared to those in normal ovarian tissue (P<0.05) while, REG4 protein expression was higher in all three tumor types than that in normal ovarian tissue (P<0.05). Higher REG4 mRNA expression was observed in mucinous carcinomas than serous carcinomas (P<0.05), and in well- and moderately-differentiated carcinomas than poorly-differentiated carcinomas (P<0.05). Survival analysis revealed an inverse relationship between REG4 expression and cumulative or relapse-free survival rates of the patients with ovarian cancer as an independent factor (P<0.05).

conclusionsOur findings indicate that aberrant REG4 expression plays an essential role in early ovarian carcinogenesis and is closely linked to mucinous ovarian tumors, differentiation and adverse prognosis of ovarian cancer by modulating proliferation, apoptosis, migration and invasion.

Indexed as

AgedApoptosisBiomarkers, TumorCarcinogenesisCarcinoma, Ovarian EpithelialCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansLectins, C-TypeMiddle AgedNeoplasms, Glandular and EpithelialOvarian NeoplasmsPancreatitis-Associated ProteinsPrognosisBiomarkers, TumorLectins, C-TypePancreatitis-Associated ProteinsREG4 protein, human

Identifiers

PMID26077911
PMCPMC4469329
OpenAlexW2131595212

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.